Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
002437.SZ
Top 10 Correlated ETFs
002437.SZ
Top 10 Correlated Stocks
002437.SZ
Financial details
Company Rating
Strong Buy
Market Cap
5.25B
Income
115.48M
Revenue
3.21B
Book val./share
0.96
Cash/share
0.66
Dividend
-
Dividend %
-
Employees
4.77K
Optionable
No
Shortable
Yes
Earnings
29 Apr 2022
P/E
239
Forward P/E
-
PEG
-33.96
P/S
1.49
P/B
2.48
P/C
3.62
P/FCF
29.65
Quick Ratio
0.52
Current Ratio
0.78
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.05
EPS next Y
-
EPS next Q
-
EPS this Y
-88.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-31.99%
Revenue last 5Y
0.67%
Revenue Q/Q
6.61%
EPS Q/Q
2491.73%
-
-
-
-
SMA20
-6.27%
SMA50
-4.4%
SMA100
-3.24%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
6%
ROC
0.1%
Gross Margin
75%
Oper. Margin
6%
Profit Margin
4%
Payout
-
Shs Outstand
2.2B
Shs Float
1.31B
-
-
-
-
Target Price
-
52W Range
2.26-3.4
52W High
-20.33%
52W Low
+19.5%
RSI
41.78
Rel Volume
0.65
Avg Volume
27.62M
Volume
17.96M
Perf Week
-3.24%
Perf Month
-7.72%
Perf Quarter
-18.15%
Perf Half Y
-18.43%
-
-
-
-
Beta
0.667381
-
-
Volatility
0.04%, 0.09%
Prev Close
1.7%
Price
2.39
Change
-0.42%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.38 | 2.49 | 2.3 | 1.39 | 1.43 | |
| Net income per share | 0.14 | 0.06 | -1.21 | 0.18 | 0.02 | |
| Operating cash flow per share | 0.3 | 0.53 | 0.28 | 0.01 | 0.12 | |
| Free cash flow per share | 0.21 | 0.48 | 0.26 | -0.01 | 0.11 | |
| Cash per share | 0.44 | 0.59 | 0.6 | 0.41 | 0.68 | |
| Book value per share | 1.9 | 1.97 | 0.69 | 0.84 | 0.86 | |
| Tangible book value per share | -0.04 | 0.19 | 0.34 | 0.53 | 0.58 | |
| Share holders equity per share | 1.9 | 1.97 | 0.69 | 0.84 | 0.86 | |
| Interest debt per share | 1.7 | 1.49 | 1.29 | 0.66 | 0.74 | |
| Market cap | 14.88B | 5.84B | 6.66B | 5.82B | 5.56B | |
| Enterprise value | 17.49B | 7.66B | 8.03B | 6.28B | 5.62B | |
| P/E ratio | 48.05 | 46.42 | -2.5 | 14.56 | 123.41 | |
| Price to sales ratio | 4.89 | 1.07 | 1.32 | 1.91 | 1.77 | |
| POCF ratio | 22.83 | 5.03 | 10.91 | 456.36 | 20.27 | |
| PFCF ratio | 32.55 | 5.52 | 11.85 | -188.51 | 23.19 | |
| P/B Ratio | 3.56 | 1.35 | 4.38 | 3.16 | 2.93 | |
| PTB ratio | 3.56 | 1.35 | 4.38 | 3.16 | 2.93 | |
| EV to sales | 5.75 | 1.4 | 1.59 | 2.06 | 1.79 | |
| Enterprise value over EBITDA | 24.34 | 14.82 | -3.52 | 7.91 | 19.17 | |
| EV to operating cash flow | 26.83 | 6.59 | 13.15 | 492.16 | 20.5 | |
| EV to free cash flow | 38.25 | 7.24 | 14.29 | -203.3 | 23.45 | |
| Earnings yield | 0.02 | 0.02 | -0.4 | 0.07 | 0.01 | |
| Free cash flow yield | 0.03 | 0.18 | 0.08 | -0.01 | 0.04 | |
| Debt to equity | 0.35 | 0.23 | 0 | 0 | 0 | |
| Debt to assets | 0.53 | 0.54 | 0.75 | 0.57 | 0.58 | |
| Net debt to EBITDA | 3.63 | 3.51 | -0.6 | 0.58 | 0.21 | |
| Current ratio | 0.62 | 0.7 | 0.67 | 0.7 | 0.82 | |
| Interest coverage | 3.33 | 4.06 | 3.04 | -0.2 | 1.34 | |
| Income quality | 2.1 | 9.24 | -0.23 | 0.03 | 6.09 | |
| Dividend Yield | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | |
| Payout ratio | 0.85 | 1.48 | -0.06 | 0.34 | 1.57 | |
| Sales general and administrative to revenue | 0.1 | 0.05 | 0.06 | 0.09 | 0.07 | |
| Research and developement to revenue | 0.03 | 0.02 | 0.04 | 0.04 | 0.03 | |
| Intangibles to total assets | 0.48 | 0.42 | 0.13 | 0.17 | 0.15 | |
| Capex to operating cash flow | -0.3 | -0.09 | -0.08 | -3.42 | -0.13 | |
| Capex to revenue | -0.06 | -0.02 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -1.11 | -0.57 | -0.27 | -0.29 | -0.24 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.45 | 1.59 | 4.34 | 1.85 | 0.63 | |
| ROIC | 0.1 | 0.12 | 0.27 | -0.01 | 0.05 | |
| Return on tangible assets | 0.07 | 0.02 | -0.48 | 0.11 | 0.01 | |
| Graham Net | -1.64 | -1.62 | -1.49 | -0.68 | -0.48 | |
| Working capital | -1.24B | -1.2B | -1.56B | -755.39M | -477.9M | |
| Tangible asset value | -95.05M | 415.4M | 742.17M | 1.17B | 1.27B | |
| Net current asset value | -2.78B | -2.27B | -1.62B | -798.27M | -515.81M | |
| Invested capital | 0.86 | 0.72 | 1.76 | 0.73 | 0.82 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 233.99M | 300.26M | 293.2M | 284.36M | 277.43M | |
| Average inventory | 420.13M | 408.64M | 413.29M | 370.96M | 361.52M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 74.87 | 82.71 | 81.85 | 130.89 | 118.99 | |
| Days of inventory on hand | 191.37 | 116.77 | 123.48 | 170.74 | 154.89 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.87 | 4.41 | 4.46 | 2.79 | 3.07 | |
| Inventory turnover | 1.91 | 3.13 | 2.96 | 2.14 | 2.36 | |
| ROE | 0.07 | 0.03 | -1.75 | 0.22 | 0.02 | |
| Capex per share | -0.09 | -0.05 | -0.02 | -0.02 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.32 | 0.38 | 0.36 | 0.39 | 0.41 | |
| Net income per share | 0.01 | 0.04 | 0 | 0 | 0.01 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0.07 | -0.02 | 0.03 | 0.02 | 0.05 | |
| Cash per share | 0.6 | 0.6 | 0.76 | 0.72 | 0.66 | |
| Book value per share | 0.85 | 0.89 | 0.89 | 0.95 | 0.96 | |
| Tangible book value per share | 0.55 | 0.6 | 0.6 | 0.64 | 0.66 | |
| Share holders equity per share | 0.85 | 0.89 | 0.89 | 0.95 | 0.96 | |
| Interest debt per share | 0.75 | 0.76 | 0.77 | 0.79 | 0.79 | |
| Market cap | 5.76B | 5.67B | 5.65B | 5.99B | 5.05B | |
| Enterprise value | 6.07B | 6.01B | 5.89B | 6.24B | 5.29B | |
| P/E ratio | 65.75 | 15.3 | -346.78 | 1.5K | 48.81 | |
| Price to sales ratio | 8.17 | 6.82 | 7.24 | 7.74 | 6.12 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 35.55 | -164.14 | 99.17 | 125.43 | 55.66 | |
| P/B Ratio | 3.08 | 2.89 | 2.89 | 3.16 | 2.63 | |
| PTB ratio | 3.08 | 2.89 | 2.89 | 3.16 | 2.63 | |
| EV to sales | 8.6 | 7.22 | 7.54 | 8.06 | 6.41 | |
| Enterprise value over EBITDA | 129.65 | 48.41 | 275.31 | 216.47 | 94.42 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 37.43 | -173.94 | 103.35 | 130.67 | 58.33 | |
| Earnings yield | 0 | 0.02 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0.03 | -0.01 | 0.01 | 0.01 | 0.02 | |
| Debt to equity | 0.01 | 0.01 | 0 | 0 | 0 | |
| Debt to assets | 0.6 | 0.58 | 0.59 | 0.56 | 0.56 | |
| Net debt to EBITDA | 6.52 | 2.73 | 11.15 | 8.69 | 4.34 | |
| Current ratio | 0.78 | 0.8 | 0.83 | 0.83 | 0.78 | |
| Interest coverage | 2.99 | 6.32 | 2.43 | 0.96 | 2.36 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.74 | 0.2 | -3.03 | 16.24 | 0.68 | |
| Sales general and administrative to revenue | 0.07 | 0.04 | 0.09 | 0.06 | 0.03 | |
| Research and developement to revenue | 0.04 | 0.02 | 0.02 | 0.03 | 0.02 | |
| Intangibles to total assets | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.44 | 0.92 | 0.19 | 0.1 | 0.53 | |
| ROIC | 0.03 | 0.05 | 0.02 | 0.01 | 0.02 | |
| Return on tangible assets | 0.01 | 0.02 | 0 | 0 | 0.01 | |
| Graham Net | -0.64 | -0.61 | -0.49 | -0.48 | -0.55 | |
| Working capital | -637.09M | -553.71M | -507.15M | -418.38M | -548.96M | |
| Tangible asset value | 1.2B | 1.31B | 1.31B | 1.28B | 1.32B | |
| Net current asset value | -689.64M | -604.17M | -544.93M | -454.94M | -584.17M | |
| Invested capital | 0.87 | 0.85 | 0.85 | 0.82 | 0.81 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 209.93M | 230.88M | 274.98M | 138.12M | 131.02M | |
| Average inventory | 364.55M | 391.64M | 389.14M | 344.4M | 312.69M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 144.61 | 147.04 | 179.82 | 66 | 53.26 | |
| Days of inventory on hand | 197.46 | 199.39 | 189.44 | 164.58 | 120.75 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.62 | 0.61 | 0.5 | 1.36 | 1.69 | |
| Inventory turnover | 0.46 | 0.45 | 0.48 | 0.55 | 0.75 | |
| ROE | 0.01 | 0.05 | 0 | 0 | 0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Frequently Asked Questions
What is Harbin Gloria Pharmaceuticals Co., Ltd stock symbol ?
Harbin Gloria Pharmaceuticals Co., Ltd is a CN stock and trading under the symbol 002437.SZ
What is Harbin Gloria Pharmaceuticals Co., Ltd stock quote today ?
Harbin Gloria Pharmaceuticals Co., Ltd stock price is $2.39 today.
Is Harbin Gloria Pharmaceuticals Co., Ltd stock public?
Yes, Harbin Gloria Pharmaceuticals Co., Ltd is a publicly traded company.
Company Profile
- Volume Average 27.62M
- Market Capitalization 5.25B
- Employee 4.77K
- Headquarters Harbin,CN
- IPO Date 2011-10-27
-
Website
https://www.gloria.cc 
Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.
